Power Law company profile

Metsera

Biotech & Life Sciences · New York City, United States · Founded 2022 · IPO 2025 Unicorn

Metsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases

Valuation

$4.90B

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

18 investors on Metsera's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage

Newpath Management

Population Health Partners

ARCH Venture Partners

F-Prime

SoftBank

Mubadala Capital

Series B+ 11 investors entered at this stage

Janus Henderson Investors

Venrock

Wellington Management

RA Capital Management

SymBiosis

Alpha Wave Global

Viking Global Investors

Fidelity Investments

Deep Track Capital

T. Rowe Price

SoftBank Vision Fund

Global footprint

Where Metsera has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States85.8%

🇬🇧 United Kingdom12.6%

🇮🇳 India1.2%

3 countries shown

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States42.7%

🏳️ Korea18.2%

🏳️ Republic of18.2%

🇬🇧 United Kingdom10.9%

🇮🇳 India8.2%

Top 5 markets shown

Market sentiment

What the market is saying about Metsera

An AI-synthesized read of the highest-engagement posts about Metsera on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Metsera on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles